JP2024538168A5 - - Google Patents

Info

Publication number
JP2024538168A5
JP2024538168A5 JP2024523142A JP2024523142A JP2024538168A5 JP 2024538168 A5 JP2024538168 A5 JP 2024538168A5 JP 2024523142 A JP2024523142 A JP 2024523142A JP 2024523142 A JP2024523142 A JP 2024523142A JP 2024538168 A5 JP2024538168 A5 JP 2024538168A5
Authority
JP
Japan
Prior art keywords
ssdna
pharmaceutical preparation
composition
item
contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538168A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078301 external-priority patent/WO2023069948A1/en
Publication of JP2024538168A publication Critical patent/JP2024538168A/ja
Publication of JP2024538168A5 publication Critical patent/JP2024538168A5/ja
Pending legal-status Critical Current

Links

JP2024523142A 2021-10-18 2022-10-18 Ｄｎａ組成物及び関連方法 Pending JP2024538168A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163262690P 2021-10-18 2021-10-18
US63/262,690 2021-10-18
US202263304913P 2022-01-31 2022-01-31
US63/304,913 2022-01-31
US202263373293P 2022-08-23 2022-08-23
US63/373,293 2022-08-23
US202263402772P 2022-08-31 2022-08-31
US63/402,772 2022-08-31
PCT/US2022/078301 WO2023069948A1 (en) 2021-10-18 2022-10-18 Dna compositions and related methods

Publications (2)

Publication Number Publication Date
JP2024538168A JP2024538168A (ja) 2024-10-18
JP2024538168A5 true JP2024538168A5 (enExample) 2025-10-27

Family

ID=86058611

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523142A Pending JP2024538168A (ja) 2021-10-18 2022-10-18 Ｄｎａ組成物及び関連方法

Country Status (8)

Country Link
US (2) US20250027107A1 (enExample)
EP (1) EP4419677A4 (enExample)
JP (1) JP2024538168A (enExample)
KR (1) KR20240113478A (enExample)
AU (1) AU2022369290A1 (enExample)
CA (1) CA3235493A1 (enExample)
IL (2) IL312184B1 (enExample)
WO (1) WO2023069948A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024246232A1 (en) * 2023-03-31 2025-10-16 Kano Therapeutics Inc. Components for genomic editing
WO2024260438A1 (zh) 2023-06-21 2024-12-26 南京金斯瑞生物科技有限公司 一种利用Cas切口酶制备单链DNA的方法
WO2025187175A1 (ja) * 2024-03-07 2025-09-12 国立研究開発法人産業技術総合研究所 組換え単純ヘルペスウイルスベクターを製造するための細胞、及び組換え単純ヘルペスウイルスベクターの製造方法
WO2025233870A1 (en) * 2024-05-08 2025-11-13 Engage Biologics Inc. Non-viral dna expression systems with reduced immunogenicity and methods of use thereof
WO2026055543A1 (en) 2024-09-06 2026-03-12 Flagship Pioneering Innovations Vii, Llc Modified dna compositions and related methods
WO2026055547A1 (en) 2024-09-06 2026-03-12 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06500014A (ja) 1990-07-25 1994-01-06 シンジーン，インコーポレイテッド 多数の核酸相補体を生成させる環状伸長法
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
WO1994003624A1 (en) 1992-08-04 1994-02-17 Auerbach Jeffrey I Methods for the isothermal amplification of nucleic acid molecules
CA2342838A1 (en) 1998-09-15 2000-03-23 Yale University Molecular cloning using rolling circle amplification
GB0018120D0 (en) 2000-07-24 2000-09-13 Fermentas Ab Nuclease
WO2006063355A2 (en) 2004-12-11 2006-06-15 Cytogenix , Inc. Cell free biosynthesis of high-quality nucleic acid and uses thereof
WO2006108423A2 (en) 2005-04-12 2006-10-19 In Situ Rcp A/S Under Founding Methods for production of oligonucleotides
US8921072B2 (en) 2008-09-02 2014-12-30 General Electric Compnay Methods to generate DNA mini-circles
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
EP2610352B1 (en) * 2009-02-16 2014-10-08 Epicentre Technologies Corporation Template-independent ligation of single-stranded DNA
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
EP2500434A1 (en) * 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
GB201303913D0 (en) 2013-03-05 2013-04-17 Touchlight Genetics Ltd Synthesis apparatus and method
GB201415789D0 (en) 2014-09-05 2014-10-22 Touchlight Genetics Ltd Synthesis of DNA
GB201502645D0 (en) 2015-02-17 2015-04-01 Touchlight Genetics Ltd Method
EP3390656B1 (en) 2015-12-14 2020-04-08 The General Hospital Corporation Methods of detecting insulator dysfunction and oncogene activation for screening, diagnosis and treatment of patients in need thereof
US11505821B2 (en) 2016-08-16 2022-11-22 Touchlight IP Limited Closed linear DNA production
EP3551169A4 (en) 2016-12-09 2020-09-09 Sangamo Therapeutics, Inc. TARGET-SPECIFIC NUCLEASES ADMINISTRATION
US20180305701A1 (en) * 2017-03-14 2018-10-25 Baylor College Of Medicine Targeting minivectors to specific tissue using shape
US11446393B2 (en) 2017-06-13 2022-09-20 Monash University Non-viral gene delivery agent comprising lipopeptide (LP) compounds
IL271275B1 (en) * 2017-06-13 2026-04-01 Flagship Pioneering Innovations V Inc Preparations containing croons and their uses
KR20200036873A (ko) 2017-07-14 2020-04-07 온코루스, 인크. 캡슐화된 폴리뉴클레오티드 및 사용 방법
CN111132699A (zh) * 2017-09-08 2020-05-08 世代生物公司 修饰的封闭端dna(cedna)
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
BR112020008568A2 (pt) 2017-11-09 2020-10-06 Sangamo Therapeutics, Inc. modificação genética de gene de proteína contendo sh2 indutível por citoquina (cish)
KR20200093635A (ko) 2017-12-06 2020-08-05 제너레이션 바이오 컴퍼니 변형된 폐쇄된 말단 dna (cedna)를 사용한 유전자 편집
WO2019118806A1 (en) 2017-12-14 2019-06-20 Solid Biosciences Inc. Non-viral production and delivery of genes
EP3759225A1 (en) * 2018-03-02 2021-01-06 Sixfold Bioscience Ltd. Compositions for delivery of cargo to cells
GB201805683D0 (en) 2018-04-05 2018-05-23 Touchlight Ip Ltd Reprogramming vectors
CN112534063A (zh) * 2018-05-22 2021-03-19 安序源有限公司 用于核酸测序的方法、系统和组合物
US20210346306A1 (en) 2018-05-23 2021-11-11 Modernatx, Inc. Delivery of dna
CA3104113A1 (en) 2018-06-22 2019-12-26 Asklepios Biopharmaceutical, Inc. Vectors for gene delivery that persist within cells
GB201813429D0 (en) 2018-08-17 2018-10-03 Touchlight Ip Ltd Synthesis of DNA with improved yield
EP3894569A2 (en) * 2018-12-12 2021-10-20 Flagship Pioneering Innovations V, Inc. Anellosomes for delivering protein replacement therapeutic modalities
EP3934700A4 (en) 2019-03-06 2022-12-14 Generation Bio Co. NON-ACTIVE LIPID NANOPARTICLES WITH CAPSID-FREE, NON-VIRAL DNA
BR112021017853A2 (pt) * 2019-03-13 2021-11-30 Generation Bio Co Vetores de dna não virais e usos dos mesmos para expressar terapêuticas de fviii
GB201905651D0 (en) 2019-04-24 2019-06-05 Lightbio Ltd Nucleic acid constructs and methods for their manufacture
MA55766A (fr) 2019-04-26 2022-03-02 Genevant Sciences Gmbh Nanoparticules lipidiques
US20220228171A1 (en) 2019-07-17 2022-07-21 Generation Bio Co. Compositions and production of nicked closed-ended dna vectors
WO2021026358A1 (en) 2019-08-07 2021-02-11 Moderna TX, Inc. Compositions and methods for enhanced delivery of agents
WO2021119585A1 (en) 2019-12-13 2021-06-17 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
GB202002068D0 (en) 2020-02-14 2020-04-01 Touchlight Ip Ltd DNA synthesis yield improvements
GB2627644B (en) 2020-03-04 2024-11-20 Verve Therapeutics Inc Method for the preparation of GalNAc-lipid nanoparticle
AU2021232005A1 (en) 2020-03-04 2022-09-29 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
AU2021244555A1 (en) 2020-03-24 2022-11-24 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
EP4125338A4 (en) 2020-03-30 2024-05-01 Inari Agriculture Technology, Inc. IMPROVED POLYNUCLEOTIDES FOR THE EXPRESSION OF RNA-GUIDED NUCLEASES AND DNA-BINDING PROTEINS IN SOYBEANS
CA3184474A1 (en) 2020-06-01 2021-12-09 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
CA3181680A1 (en) 2020-06-12 2021-12-16 University Of Rochester Encoding and expression of ace-trnas
TW202221126A (zh) 2020-06-17 2022-06-01 美商旗艦先鋒創新公司 用於鑑別及特徵化指環病毒之方法及其用途
GB202015399D0 (en) 2020-09-29 2020-11-11 Evox Therapeutics Ltd Engineered extracellular vesicles displaying enhanced pharmacokinetics
MX2023005040A (es) 2020-10-29 2023-06-02 Flagship Pioneering Innovations V Inc Vectores basados en el virus de la anemia del pollo (cav).
CA3205138A1 (en) 2020-12-17 2022-06-23 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
US20240181085A1 (en) 2021-03-19 2024-06-06 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing pfic therapeutics

Similar Documents

Publication Publication Date Title
US12116571B2 (en) Compositions and methods for detecting nucleic acid regions
US20240277872A1 (en) Modified mrna, modified non-coding rna, and uses thereof
CN109844113B (zh) 序列和长度确定的dna单链分子的可扩展性的生物技术生产
Van Dijk et al. Library preparation methods for next-generation sequencing: tone down the bias
EP3464323B1 (en) Peptides and nanoparticles for intracellular delivery of genome-editing molecules
EP4163374A1 (en) Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
EP4227412A1 (en) Engineered guide rna for increasing efficiency of crispr/cas12f1 (cas14a1) system, and use thereof
CN110291198A (zh) 经修饰的指导rna
Kupryushkin et al. Antisense oligonucleotide gapmers containing phosphoryl guanidine groups reverse MDR1-mediated multiple drug resistance of tumor cells
CA3036409A1 (en) Dnase h activity of neisseria meningitidis cas9
US20210269851A1 (en) Massively parallel discovery methods for oligonucleotide therapeutics
US20240327449A1 (en) Structure-based design of antisense oligonucleotide drugs
CN101126176A (zh) PCR高通量构建siRNA全位点分子库制备方法
US20220017895A1 (en) Gramc: genome-scale reporter assay method for cis-regulatory modules
Li et al. EcCas6e-based antisense crRNA for gene repression and RNA editing in microorganisms
EP3665306B1 (en) Rna identity method using rnase h digestion and size fractionating
EP4477754A2 (en) Target system for homology-directed repair and gene editing method using same
CN118076741A (zh) 修饰的mRNA、修饰的非编码RNA及其用途
CA3199080A1 (en) Methods and kits for enriching for polynucleotides
US20240425850A1 (en) Noncanonical crRNA for Highly Efficient Genome Editing
WO2024259135A1 (en) Assays for analysis of ribonucleic acid (rna) molecules
WO2026107352A1 (en) Compositions and methods for efficient nucleic acid assembly and tissue engineering
WO2026057749A1 (en) Method and product
HK40058153A (en) Compositions and methods for detecting nucleic acid regions
Coppins Deoxyribozymes that prepare branched and linear RNA by ligation